Summit Therapeutics says ivonescimab meets primary endpoint in Phase II endometrial cancer study
SMMT•Summit Therapeutics said ivonescimab monotherapy met the tumor response goal in a Phase II endometrial cancer study, with manageable safety and no new safety signals. The results supported expansion of the investigator-sponsored trial.
1. Endometrial cancer results
Ivonescimab monotherapy met the tumor response goal in a Phase II endometrial cancer study, with manageable safety and no new safety signals. The results supported expansion of the investigator-sponsored trial.
2. Other study updates
Summit Therapeutics will feature 10 ivonescimab presentations at ESMO 2026, scheduled for October 23-27 in Madrid. Akeso's China-based Phase III HARMONi-GI1 trial showed positive overall survival findings versus durvalumab, both with chemotherapy, in first-line advanced biliary tract cancer; a separate US Phase II/III biliary tract cancer trial with ECOG-ACRIN expects clinical site activation in the fourth quarter of 2026.
